GlassScriptPhysician profile
Swetha Murthi
NPI 1588028484
$390.40
in general payments reported to CMS, 2019-2025
11 companies · $117 in 2025
The $117 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $44.72 · 2023: $106 · 2024: $122 · 2025: $117.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $346.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $345.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $87.78 | 2023-2024 | |
| Tandem Diabetes Care, INC. | $70.40 | 2022-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Astellas Pharma US INC | $46.05 | 2024 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.46 | 2025 | Jardiance |
| Glaxosmithkline, LLC. | $29.98 | 2023-2024 | Benlysta |
| Medtronic, INC. | $24.89 | 2024 | Minimed 780g |
| Recordati_rare_diseases_inc. | $21.90 | 2023 | Isturisa, Signifor Lar |
| Novo Nordisk INC | $20.61 | 2025 | Ozempic |
| Abbvie INC. | $20.55 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $19.08 | 2022 | |
| Dexcom, INC. | $16.70 | 2025 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Swetha Murthi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.